DOI QR코드

DOI QR Code

Survival of Patients with Ewing's Sarcoma in Yazd-Iran

  • Akhavan, Ali (Department of Radiotherapy, Isfahan University of Medical Sciences) ;
  • Binesh, Fariba (Department of Pathology, Shahid Sadoughi University of Medical Sciences) ;
  • Shamshiri, Hadi (General Practitioner, Shahid Sadoughi University of Medical Sciences) ;
  • Ghanadi, Fazllolah (Scientific Editor and English Translator, Isfahan University of Medical Sciences)
  • Published : 2014.06.30

Abstract

Background: The Ewing's sarcoma family is a group of small round cell tumors which accounts for 10-15% of all primary bone neoplasms. The aim of this study was to evaluate the survival of Ewing's sarcoma patients in our province and to determine of influencing factors. Materials and Methods: All patients with documented Ewing's sarcoma/primitive neuroectodermal tumor(PNET) family pathology were enrolled in this study during a period of eight years. For all of them local and systemic therapy were carried out. Overall and event free survival and prognostic factors were evaluated. Results: Thirty two patients were enrolled in the study. The median age was 17.5 years. Twenty (65.2%) were male and 9 (28.1%) were aged 14 years or less. Mean disease free survival was 26.8 (95%CI; 13.8-39.9) months and five year disease free survival was 26%. Mean overall survival was 38.7 months (95%CI; 25.9-50.6) and median overall survival was 24 months. Five year overall survival was 25%. From the variables evaluated, only presence of metastatic disease at presentation (p value=0. 028) and complete response (p value =0. 006) had significant relations to overall survival. Conclusions: Survival of Ewing's sarcoma in our province is disappointing. It seems to be mostly due to less effective treatment. Administration of adequate chemotherapy dosage, resection of tumor with negative margins and precise assessment of irradiation volume may prove helpful.

References

  1. Grier HE, Krailo MD, Tarbell NJ, et al (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med, 348, 694-701. https://doi.org/10.1056/NEJMoa020890
  2. Tural D,Molinas Mandel N, Dervisoglu S, et al (2012). Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome. Jpn J Clin Oncol, 42, 420-6 https://doi.org/10.1093/jjco/hys027
  3. Weston CL, Douglas C, Craft AW, et al (2004). Establishing long-term survival and cure in young patients with Ewing's sarcoma. Br J Cancer, 91, 225-32. https://doi.org/10.1038/sj.bjc.6601955
  4. Womer RB WD, Krailo MD, Dickman PS, et al (2008). Randomized comparison of every-two-week v. everythree-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol, 26, 50-4.
  5. Ghasemi A, Hiradfar AA, Pedram Mohammad (2010). An epidemiologic study of ewing sarcoma family at shafa hospital in khozestan province-iran, a referral children cancer treatment center. Iran J Ped Hematol Oncol, 1, 24-6.
  6. Ginsberg JP, Goodman P, Leisenring W, et al (2010). Longterm survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst, 102, 1272-83. https://doi.org/10.1093/jnci/djq278
  7. Haeusler J, Ranft A, Boelling T, et al (2010). The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer, 116, 443-50. https://doi.org/10.1002/cncr.24740
  8. Rosito P, Mancini AF, Rondelli R, et al (1999). Italian cooperative study for the treatment of children and young adults with localized Ewing sarcoma of bone. Cancer, 86, 421-8. https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<421::AID-CNCR10>3.0.CO;2-O
  9. Seker MM, Kos T, Ozdemir N, et al (2014). Treatment and outcomes of Ewing sarcoma in Turkish adults: a single centre experience. Asian Pac J Cancer Prev, 15, 327-30. https://doi.org/10.7314/APJCP.2014.15.1.327
  10. Solooki S, Vosoughi AR, Masoomi V (2011). Epidemiology of musculoskeletal tumors in Shiraz, south of Iran. Indian journal of medical and paediatric oncology: Indian J Med Paediatr Oncol, 32, 187-91. https://doi.org/10.4103/0971-5851.95138
  11. Somarouthu BS, Shinagare AB, Rosenthal MH, et al (2014). Multimodality imaging features, metastatic pattern and clinical outcome in adult extraskeletal Ewing sarcoma: experience in 26 patients. Br J Radiol, 20140123.
  12. Tao HT, Hu Y, Wang JL, et al (2013). Extraskeletal Ewing sarcomas in late adolescence and adults: a study of 37 patients. Asian Pac J Cancer Prev, 14, 2967-71. https://doi.org/10.7314/APJCP.2013.14.5.2967
  13. Oberlin O, Deley MC, Bui BN, et al (2001). Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer, 85, 1646-54. https://doi.org/10.1054/bjoc.2001.2150
  14. Mameghan H, Fisher RJ, O'Gorman-Hughes D, et al (1993). Ewing's sarcoma: long-term follow-up in 49 patients treated from 1967 to 1989. Int J Radiat Oncol Biol Phys, 25, 431-8. https://doi.org/10.1016/0360-3016(93)90064-3
  15. Nesbit ME Jr., Gehan EA, Burgert EO, et al (1990). Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol, 8, 1664-74. https://doi.org/10.1200/JCO.1990.8.10.1664
  16. Obata H, Ueda T, Kawai A, et al (2007). Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer, 109, 767-75. https://doi.org/10.1002/cncr.22481
  17. Robert B M, Jr (2008). Ewing Tumor. In: Edward C. Halperin CAP, Luther W. Brady, editor. Perez and Brady's Principles and Practice of Radiation Oncology. 5 ed. Philadelphia, USA: Wolters Kluwer$\mid$Lippincott, Williams & Wilkins. p. 1886.
  18. Abou Ali B, Nader R, Tamim H, et al (2014)Outcome of Ewing sarcoma in a multidisciplinary setting in Lebanon. Pediatr Blood Cancer.
  19. Baldini EH, Demetri GD, Fletcher CD (1999), Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg, 230, 79-86. https://doi.org/10.1097/00000658-199907000-00012
  20. Burchill S (2003). Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol, 56, 96-102. https://doi.org/10.1136/jcp.56.2.96
  21. Cangir A, Vietti TJ, Gehan EA, et al (1990). Ewing's sarcoma metastatic at diagnosis. Cancer, 66, 887-93. https://doi.org/10.1002/1097-0142(19900901)66:5<887::AID-CNCR2820660513>3.0.CO;2-R
  22. Lisa L, Wang JY, Chrystal Louis, et al (2013). Solid Tumors of Childhood In: DeVita H, and Rosenberg's Cancer: Principles & Practice of Oncology, editor. Cancer: Principles & Practice of Oncology Philadelphia,USA: Wolters Kluwer Lippincott, Williams & Wilkins, 1774.
  23. Jurgens H, Exner U, Gadner H, et al (1988). Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer, 61, 23-32. https://doi.org/10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M
  24. Leavey PJ, Mascarenhas L, Marina N, et al (2008). Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multimodality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer, 51, 334-8. https://doi.org/10.1002/pbc.21618
  25. Lee JA, Kim DH, Cho J, et al (2011). Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience. Jpn J Clin Oncol, 41, 776-82. https://doi.org/10.1093/jjco/hyr033
  26. Lopez Guerra JL, Marquez-Vega C, Ramirez-Villar GL, et al (2012). Prognostic factors for overall survival in paediatric patients with Ewing sarcoma of bone treated according to multidisciplinary protocol. Clin Transl Oncol, 14, 294-301. https://doi.org/10.1007/s12094-012-0798-y